



Submitted by: Jack Jennings, MD, PhD, Professor, Washington University,
Joseph Erinjeri MD, PhD, Associate Professor, Memorial Sloan Kettering Cancer Center,
Daehee Kim MD, Assistant Professor, Memorial Sloan Kettering Cancer Center.

Organization:
Society of Interventional Oncology
2025 M St NW #800, Washington, DC 20036
[Phone:](tel:(202)367-1164) (202) 367-1164
[Email:](mailto:TGreene@sio-central.org) TGreene@sio-central.org

June 8, 2020
NCCN Guidelines Panel: Soft Tissue Sarcoma

On behalf of the Society of Interventional Oncology, we respectfully request the NCCN Soft Tissue Sarcoma Guideline panel review the enclosed data for inclusion in the management of soft tissue sarcomas.

Specific Change 1: EXTSARC-6 Single organ with limited tumor bulk that are amenable to local therapy → ablation 13/146

Add Foot note gg-- Ablation of sarcoma metastases can provide extended systemic chemotherapy and progression free intervals of greater than 1 year and may improve patient quality of life by extending the chemotherapy-free interval.

References:
Sutton C, Zhang Y, Kim D, Yarmohammadi H, Ziv E, Boas FE, Sofocleous CT, Tap WD, D'Angelo SP, Erinjeri JP. Analysis of the Chemotherapy-Free Interval following Image-Guided Ablation in Sarcoma Patients. *Sarcoma*. 2020 Feb 14;2020:3852420. doi: 10.1155/2020/3852420. eCollection 2020.

Hirbe AC, Jennings JW, Saad N, Giardina JD, Tao Y, Luo J, Berry S, Toeniskoetter J, Van Tine BA. A Phase II Study of Tumor Ablation in Patients with Metastatic Sarcoma Stable on Chemotherapy. *Oncologist*. 2018 Jul;23(7):760-e76. doi: 10.1634/theoncologist.2017-0536. Epub 2018 Feb 27. PubMed PMID: 29487221; PubMed Central PMCID: PMC6058323

Specific Change 2: GIST-5 Progression → Limited → ablation or embolization or chemoembolization 23/146

Add Foot note bb-- Hepatic artery embolization should be considered as an alternative or adjuvant to third-line or even second-line systemic treatment with overall survival of ≥ 15 months when used as second or third line therapy.

References:
Haruyuki Takaki¹, Tess Litchman, Ann Covey, Francois Cornelis, Majid Maybody, George I Getrajdman, Constantinos T Sofocleous, Karen T Brown, Stephen B Solomon, William Alago,

Joseph P Erinjeri. Hepatic artery embolization for liver metastasis of gastrointestinal stromal tumor following imatinib and sunitinib therapy. *J Gastrointest Cancer*. 2014 Dec;45(4):494-9. doi: 10.1007/s12029-014-9663-2.

Cao G, Li J, Shen L, Zhu X. Transcatheter arterial chemoembolization for gastrointestinal stromal tumors with liver metastases. *World J Gastroenterol*. 2012;18(42):6134-6140. doi:10.3748/wjg.v18.i42.6134

Specific Change 3: SARC-D Biopsy 45/146

“Image guided needle biopsy may be necessary for extremity/trunk sarcomas.”

Add: For a primary tumor biopsy, the trajectory for biopsy should be planned based on the lesion to possible subsequent resection of the lesion and biopsy tract. In this setting, biopsy planning may avoid potential seeding which could jeopardize limb salvage surgeries, or increase morbidity/mortality.

Reference:

Liu PT, Valadez SD, Chivers FS, Roberts CC, Beauchamp CP. Anatomically based guidelines for core needle biopsy of bone tumors: implications for limb-sparing surgery. *Radiographics* 2007;27(1):189–205.

Hillen TJ, Baker JC, Jennings JW, Wessell DE. Image-guided biopsy and treatment of musculoskeletal tumors. *Semin Musculoskelet Radiol*. 2013 Apr;17(2):189-202. doi: 10.1055/s-0033-1343096. Epub 2013 May 14. Review. PubMed PMID: 23673550.

Specific Change 4: EXTSARC-6 Metastatic Disease→ Single organ with limited tumor bulk that are amenable to local therapy and disseminated metastases→embolization procedures 13/146

Change embolization procedure to embolization procedure (TAE/TACE/SIRT) (to include Y90) in “single organ with limited tumor bulk that are amenable to local therapy and disseminated metastases.”

Add Footnote hh—transarterial embolization (TAE), transarterial chemoembolization (TACE) and selective internal radiation therapy (SIRT) in metastatic soft tissue sarcoma of the liver are safe salvage therapies with high rates of disease control and overall survival.

Reference:

Maluccio MA, Covey AM, Schubert J, Brody LA, Sofocleous CT, Getrajdman GI, DeMatteo R, Brown KT. Treatment of metastatic sarcoma to the liver with bland embolization. *Cancer*. 2006 Oct 1;107(7):1617-23. doi: 10.1002/cncr.22191.

Chapiro J, Duran R, Lin M, Mungo B, Schlachter T, Schernthaner R, Gorodetski B, Wang Z, Geschwin JF. Transarterial Chemoembolization in Soft-Tissue Sarcoma Metastases to the Liver - The Use of Imaging Biomarkers as Predictors of Patient Survival. *Eur J Radiol*. 2015 Mar; 84(3):424-430.doi: 10.1016/j.ejrad.2014.11.034. Epub 2014 Dec 13.

Miller MD, Sze DY, Padia SA, Lewandowski RJ, Salem R, Mpofu P, Haste PM, Johnson MS. Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma: A Multicenter Retrospective Study. *J Vasc Interv Radiol*. 2018 Jun;29(6):867-873.doi: 10.1016/j.jvir.2018.01.775. Epub 2018 Apr 30.

We would like to thank the NCCN panel members for their time and effort in reviewing this submission.

Sincerely,
Jack Jennings MD, PhD
Joe Erinjeri MD, PhD
Daehee Kim MD